DDInter1042 DDInter1778
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
Tetrabenazine {u} (Compound) resembles {v} (Compound) Donepezil
Tetrabenazine {u} (Compound) binds {v} (Gene) CYP2D6
Tetrabenazine {u} (Compound) upregulates {v} (Gene) WDR61
Tetrabenazine {u} (Compound) is included by {v} (Pharmacologic Class) Vesicular Monoamine Transporter 2 Inhibitors
Tetrabenazine {u} (Compound) downregulates {v} (Gene) GJA1
Tetrabenazine {u} (Compound) causes {v} (Side Effect) Insomnia
Tetrabenazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Tetrabenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Tetrabenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Tetrabenazine {u} may lead to a major life threatening interaction when taken with {v} Osimertinib
Tetrabenazine (Compound) resembles Donepezil (Compound)
Tetrabenazine (Compound) binds CYP2D6 (Gene)
Tetrabenazine (Compound) upregulates WDR61 (Gene)
Tetrabenazine (Compound) is included by Vesicular Monoamine Transporter 2 Inhibitors (Pharmacologic Class)
Tetrabenazine (Compound) downregulates GJA1 (Gene)
Tetrabenazine (Compound) causes Insomnia (Side Effect)
Tetrabenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Tetrabenazine may lead to a major life threatening interaction when taken with Osimertinib